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Highlights for review 22 
- Dysregulated social perception is a possible causative factor for interpersonal difficulties in BN 23 
- Oxytocin inhibits the amygdala response to threat and modulates emotional reactivity 24 
- BN shows a similar increase in attentional processes to anger as the healthy comparison group  25 
- Intranasal oxytocin reduced the attentional bias to anger in both BN and the healthy comparison 26 
group 27 
 28 
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Abstract 29 
 30 
Background: Bulimia nervosa (BN) is characterized by binge eating and emotional dysregulation 31 
including increased negative affectivity (anger, anxiety). The aim of this study was to examine the 32 
effect of oxytocin on attentional processes towards anger in patients with BN. 33 
Method: The study design consisted of a double-blind, placebo-controlled within-subject crossover, 34 
single dose experiment. Sixty-four women (31 patients with BN and 33 healthy comparisons) 35 
completed self-reported measures to evaluate emotional difficulties and were administered a single 36 
dose of intranasal oxytocin (40IU) or placebo followed by a visual probe detection task to examine 37 
attentional orienting to angry or happy faces.  38 
Results: Patients with BN reported higher emotional dysregulation and more difficulties in controlling 39 
anger compared to the healthy comparison group. Patients with BN and the healthy women exhibited 40 
similar attentional bias to angry faces in the placebo condition. Intranasal oxytocin reduced the 41 
attentional bias towards angry faces in both the BN patients and the healthy women. 42 
Conclusions: We found that a single dose of oxytocin reduced vigilance towards angry faces in 43 
patients with BN as well as healthy women. The results showed that patients with BN are not different 44 
from healthy women in terms of vigilance towards threat.  45 
 46 
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1. Introduction  53 
A recent maintenance model of bulimia nervosa (BN) has proposed that elevated impulsivity, 54 
sensitivity to punishment, and interpersonal difficulties reduce the rewarding aspects of social 55 
interaction (Treasure et al., 2018). This in turn is believed to feed into increased emotion dysregulation, 56 
shame, and information processing biases, leading to greater reliance on eating as a coping mechanism 57 
and source of reward. The model is supported by findings that people with BN show increased 58 
attention and sensitivity towards negative social cues (Caglar-Nazali et al., 2014; Cardi et al., 2014; 59 
Cardi et al., 2013). Observational studies have also reported that binge eating episodes are frequently 60 
preceded by negative affect, especially anger and interpersonal distress (Haedt-Matt and Keel, 2011). 61 
Moreover, experimental studies have found that people with BN are characterized by a high propensity 62 
to express anger inadequately (Krug et al., 2008), which can lead to binge eating through impulsive 63 
emotional dysregulation (Amianto et al., 2012). Furthermore the trajectory of improvement in 64 
emotional regulation associated with treatment varies between eating disorders with the most change 65 
found in BN (Mallorqui-Bague et al., 2018). 66 
Oxytocin, a neuropeptide, has a central role in neural circuits involved in social behaviour, 67 
appetite, anxiety, and stress. Previous work has suggested that oxytocin plays an important role in 68 
regulating social cognition by altering amygdala and prefrontal reactivity to social cues (Guastella and 69 
MacLeod, 2012; Ross and Young, 2009). Improvements in emotion recognition and theory of mind, 70 
and increased attention towards positive social cues following intranasal oxytocin among healthy 71 
people (Bakermans-Kranenburg and van, 2013; Domes et al., 2013; Macdonald and Macdonald, 2010). 72 
Oxytocin might contribute to the etiology of eating disorders, and social cognition is one of these 73 
pathways (Giel et al., 2018). Our pilot study found intranasal oxytocin similarly improved emotion 74 
recognition sensitivity in BN and healthy people (Kim et al., 2015), which suggested that reactivity to 75 
emotional stimuli may be a greater source of difficulties in BN and therefore, examining the effects of 76 
oxytocin in this area would be of interest. 77 
The aim of the study was to build on existing literature and examine the impact of a single 78 
dose of intranasal oxytocin on attentional bias towards emotional cues in BN. As anger in particular is 79 
believed to play an important role in the maintenance of disordered eating in BN, we were interested 80 
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in examining the impact of intranasal oxytocin on attentional reactivity to angry in addition to happy 81 
and neutral faces. Our first hypothesis was that patients with BN would show increased attention to 82 
angry faces due to sensitivity towards negative social cues. Our second hypothesis was that oxytocin 83 
would reduce attentional bias towards anger and increase the bias towards positive and neutral faces in 84 
BN. 85 
  86 
2. Materials and methods 87 
2.1. Participants  88 
Sixty-four young women [31 patients with BN and 33 healthy comparisons (HC)] took part in 89 
this study. Patients with BN were recruited from the outpatient clinic of Eating Disorders Clinic at 90 
Seoul Paik Hospital, Seoul, South Korea. The BN diagnosis was confirmed using a Structured Clinical 91 
Interview (First et al., 2007) based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth 92 
Edition (DSM-5). The exclusion criteria for patients were as follows: active substance use disorder 93 
and psychotic disorder. Those who had other comorbidities were allowed. In the sample, the common 94 
psychiatric comorbid disorders were depressive disorders (n=13), anxiety disorders (n=8) and 95 
borderline personality disorder (n=7) based on DSM-5. Other than the 7 patients who were taking 96 
fluoxetine, patients who were taking psychiatric medications were excluded. 97 
The HC participants were students from the women’s university in Seoul, South Korea. The 98 
inclusion criteria were healthy females without a history of medical or psychiatric illnesses, not taking 99 
regular medication including the contraceptive pill, and a minimum age of 17 years. The exclusion 100 
criteria were as follows: self-reported history of psychiatric, developmental, or neurological disorders, 101 
and substance dependence.  102 
The sample size was based on an a priori power analysis conducted with G*Power (Faul et al., 103 
2007), which indicated a minimum sample size of 60 (power = 0.8) to detect significant effects. All 104 
participants provided written informed consent prior to participating in the study. The study protocol 105 
was approved by both the Korean Food and Drug Association Institutional Review Board (approval 106 
number: 12061) and the Institutional Review Board of Seoul Paik Hospital (approval number: IIT-107 
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2012-096). This study was registered with the Clinical Research Information Service 108 
(http://cris.nih.go.kr) (registration number: KCT0000716). 109 
 110 
2.2. Experimental design  111 
We applied a double-blind, placebo-controlled, within subjects, crossover design. The 112 
preparation methods for the oxytocin and placebo are shown in Supplementary Information 1. 113 
Participants without amenorrhea (n = 61) were tested during the follicular phase of their menstrual 114 
cycle (approximately days 3 through 12). All participants received a single dose of both oxytocin (40 115 
IU per dose) and placebo in separate sessions in accordance with current guidelines (Carson et al., 116 
2013). Each participant visited the laboratory twice for testing: once for the placebo condition and 117 
once for the oxytocin condition. The order of the placebo or oxytocin administration for each 118 
participant was determined randomly by a project coordinator who was not involved in the 119 
experiment. The visual probe detection task commenced 45 minutes after the intranasal administration 120 
of oxytocin or placebo. For further details please see Supplementary Information 2.  121 
 122 
2.3. Measurements 123 
2.3.1. Self-reported psychometric assessments 124 
All participants completed self-reported measures to evaluate emotional difficulties and 125 
eating disorders psychopathology. For further details please see Supplementary Information 3. 126 
 127 
2.3.2. Visual probe detection task 128 
A visual probe detection task was used to measure attentional biases. The stimuli consisted 129 
of happy (n = 15), angry (n = 15), and neutral (n = 15) facial expressions of 15 adults were selected 130 
from 2 databases of Korean facial expressions of emotion (Lee et al., 2013; Park et al., 2011). An 131 
emotional and a neutral face were presented simultaneously, side by side on a screen followed by a 132 
probe either at the target’s location (emotional face) or at the distractor’s location (neutral face). A 133 
fixation cross was displayed at the centre of the screen for 750 ms followed by the target and non-134 
target stimuli pair for 1,000 ms. The reaction time (RT) was measured from the onset of the visual 135 
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probe following the prime until the button press. For further details please see Supplementary 136 
Information 4. 137 
2.4. Statistical analysis 138 
We followed a standard analytical procedure for the visual probe detection task (Bradley et 139 
al., 1999). Only RTs from trials in which probes were correctly identified were included in the 140 
analysis. The correct response rates were 99.9% for the BN group and 99.7% for the HC group. Mean 141 
RTs were calculated for each participant, and the outlier trials were removed by excluding detection 142 
latencies beyond two standard deviations from their mean (i.e., from each individual’s mean RTs 143 
across all stimuli).  144 
Attentional bias (AB) was calculated for each matched trial type (happy-neutral, angry-145 
neutral) by subtracting the mean RT for probes replacing the emotional prime from the mean RT for 146 
probes replacing the neutral prime. A positive AB indicated increased attention for the emotional 147 
prime while a negative AB indicated attention away from the emotional prime. The AB data were 148 
analyzed by a 2x2x2 mixed linear model using SPSS 23 (SPSS Inc., Chicago, IL, USA). The drugs 149 
(oxytocin and placebo), emotions (happy and angry), and groups (BN and HC) were entered as fixed 150 
effects while the subjects were the random effect. Multiple models were built to evaluate the model fit 151 
based on variance-covariance structures. Based on the results from the 2 Log Likelihood, the Akaike 152 
Information Criterion, and the Schwarz Bayesian Criterion, final models with a diagonal structure 153 
were reported (Littell et al., 2000). The significant interactions were post hoc tested with simple 154 
effects tests, and the effect sizes for independent and dependent t-tests are reported using Cohen’s d. 155 
Statistical significance was set at p < 0.05.  156 
 157 
3. Results 158 
3.1. Demographic and clinical characteristics 159 
Demographic and clinical characteristics of the participants are summarized in Table 1. 160 
Ages, body mass indexes (BMI, kg/m2), and IQ levels were not significantly different among the 161 
patients with BN and the HC participants.  162 
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 163 
(Table 1. Clinical characteristics of patients with bulimia nervosa and the healthy comparisons) 164 
 165 
3.2. Attentional bias to anger/happy expression faces  166 
The AB scores among the BN and HC groups following oxytocin and placebo administration 167 
are presented in Table 2. The mixed model revealed no effects from the Drug x Emotion x Group 168 
interaction [F(1,228.082) = 0.002, p = 0.965] or Emotion [F(1,228.082) = 0.136, p = 0.712] on the AB 169 
scores. However, there were effects from the Drug x Emotion interactions [F(1,228.082) = 6.413, p = 170 
0.012] and Drug [F(1,228.082) = 6.118, p = 0.014] on the AB scores. Oxytocin significantly reduced 171 
the AB towards angry faces in both the patients with BN and HC participants. A simple effect test 172 
showed that the AB to angry faces was reduced by oxytocin [F(1,120.632) = 10.217, p = 0.002] 173 
whereas the AB to happy faces was not [F(1,118.034) = 0.002, p = 0.962]. Figure S1 for AB scores is 174 
presented in Supplementary Information 5. In addition, we explored whether oxytocin induced 175 
changes in the AB scores correlated with psychometric variables or not. The results are shown in 176 
Supplementary Information 6 and 7, and further investigation was not carried out as there were no 177 
differences in AB between the BN and HC groups.  178 
 179 
(Table 2. Attentional bias scores (in ms) towards angry and happy faces in the visual probe task for 180 
the oxytocin or placebo sessions in patients with bulimia nervosa and the healthy comparisons) 181 
 182 
4. Discussion 183 
The aim of this study was to examine the effect of intranasal oxytocin on the attentional 184 
reactivity to anger in patients with BN. The findings revealed that relative to the HC group, the BN 185 
participants did not show greater AB towards anger in the placebo condition. Instead, both groups 186 
showed similar vigilance towards the angry faces, which was attenuated by intranasal oxytocin.  187 
The present findings are supported by previous findings reporting positive impact of intranasal 188 
oxytocin on social cognition and cooperation among healthy individuals (Bakermans-Kranenburg and 189 
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van, 2013; Domes et al., 2013; Macdonald and Macdonald, 2010). Moreover, findings from our 190 
previous work also showed that oxytocin similarly improved sensitivity to recognize basic emotions 191 
among the BN and HC participants (Kim et al., 2015). Therefore, taken together these findings suggest 192 
that intranasal oxytocin may have a generally positive impact on social-emotional processing. 193 
In the context of the maintenance model of BN (Treasure et al., 2018), the present findings are 194 
encouraging that intranasal oxytocin could help to reduce elevated sensitivity to negative social cues, 195 
which in turn could help to alleviate information processing biases. Thus, ultimately intranasal 196 
oxytocin could potentially help to break the loop in BN. However, it is of importance to note that the 197 
present study did not find a group difference in AB towards anger or on the effects of oxytocin on AB. 198 
Thus, research with larger sample size may be needed to explore this possibility further.  199 
In this study, taking fluoxetine was accepted as an inclusion criterion. Although, it is a 200 
common clinical practice for treating BN, it might be confounding the effect of oxytocin on AB as 201 
SSRIs may modify specific neural dysfunctions correlated to negative cognitive biases (Di Simplicio 202 
et al., 2012). Therefore, the effect of fluoxetine on oxytocin and AB needs to be investigated in a 203 
further study. 204 
The main limitation of the present study was the relatively small sample size, which 205 
prevented further exploration of the potential confounding effects of individual differences, including 206 
childhood trauma and comorbid diagnoses. Additionally, a recent meta-analysis reported that the 207 
visual probe task may not be optimal for measuring AB and recommended that future studies should 208 
opt for more sensitive measures to examine the effects of oxytocin in AB (Leppanen et al., 2018). 209 
Third, the comorbid psychiatric disorders might influence the effect of oxytocin and AB. Finally, as 210 
the study was carried with a Korean sample, the study needs to be replicated for other racial ethnic 211 
populations to determine the generalizability of the findings. 212 
In conclusion, patients with BN show similar increased attention to threat stimuli, and similar 213 
moderation effects with oxytocin as found in healthy comparison group. 214 
 215 
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 303 
Table 1. Clinical characteristics of patients with bulimia nervosa and the healthy comparisons 304 
Characteristics BN (N=31) HC (N=33) t p d 
Age, years 23.87(3.99) 22.45(2.22) 1.76 0.082 0.42 
Age of onset, years 19.90(4.72) NA NA NA NA 
BMI, kg/m2 20.79(2.62) 20.85(2.40) -0.08 0.932 0.02 
Intelligence 106.44(13.79) 111.20(6.28) -1.69 0.096 0.44 
EDE-Q      
 Restraint 2.1(1.76) 0.87(0.86) 3.53 0.001 0.89 
 Eating Concern 2.77(1.67) 0.60(0.77) 6.56 <0.001 1.68 
 Shape Concern 3.50(1.58) 1.68(1.11) 5.25 <0.001 1.34 
 Weight Concern 4.04(1.46) 2.44(1.20) 4.72 <0.001 1.20 
 Global 3.11(1.36) 1.40(0.85) 5.93 <0.001 1.51 
BDI 18.52(12.23) 7.58(7.00) 4.31 <0.001 1.09 
STAI      
 State 53.65(13.16) 43.03(11.52) 3.37 0.001 0.85 
 Trait 57.81(12.32) 44.03(11.32) 4.58 <0.001 1.16 
STAXI       
Anger_State 13.55(7.97) 11.79(4.99) 1.06 0.290 0.26 
Anger_Trait 22.06(7.26) 18.73(6.13) 1.99 0.051 0.49 
Anger_Supression 19.81(4.85) 17.79(4.27) 1.77 0.082 0.44 
Anger_Expression 17.32(4.43) 15.03(3.95) 2.18 0.032 0.54 
Anger_Control 19.35(5.35) 19.24(4.92) 0.08 0.930 0.02 
DERS      
Non-acceptance 16.42(6.18) 9.82(5.64) 4.46 <0.001 1.11 
Goals 17.03(3.71) 13.90(2.91) 3.69 <0.001 0.93 
Impulsivity 15.74(5.20) 11.85(5.07) 3.03 0.004 0.75 
Awareness 17.65(4.90) 19.68(3.92) -1.80 0.076 0.45 
Strategies 21.68(6.34) 15.16(5.69) 4.25 <0.001 1.08 
Clarity 12.65(2.60) 12.97(1.74) -0.57 0.568 0.14 
Data are shown as mean (SD). d = Cohen’s d, BN = bulimia nervosa, HC = healthy comparison, BMI = body mass 
index, EDE-Q = Eating Disorders Examination Questionnaire, BDI = Beck Depression Inventory; STAI-State, 
Spielberger State and Trait Anxiety Inventory State Score, STAI-Trait = Spielberger State and Trait Anxiety Inventory 
Trait score, STAXI = State and the Trait Anger Expression Inventory, DERS = Difficulties in Emotion Regulation Scale, 
Non-acceptance = non-acceptance of emotional responses, Goal = difficulties engaging in goal-directed behaviour, 
Impulsivity = impulse control difficulties, Awareness = lack of emotional awareness, Strategies = limited access to 
emotion regulation strategies, Clarity = lack of emotional clarity, NA = Not applicable 
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Table 2. Attentional bias scores (in ms) towards angry and happy faces in the visual probe detection task for the 305 
oxytocin or placebo sessions in patients with bulimia nervosa and the healthy comparisons 306 
Prime face 
BN (n=31) 
t(df=30) p d 
HC (n=33) 
t(df=32) p d 
Placebo Oxytocin Placebo Oxytocin 
Happy 10.68(79.96) 9.72(74.34) 0.04 0.967 0.01 11.55(71.99) 13.72(58.35) -0.14 0.889 -0.03 
Angry 40.44(95.34) -12.10(90.34) 2.67 0.012 0.47 39.76(101.35) -9.51(74.97) 2.17 0.037 0.37 
Data are shown as mean (SD). Analyzed by paired t-test. BN = bulimia nervosa, HC = healthy comparison, d = Cohen’s d. 
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Supplementary Information 1 334 
Preparation of oxytocin and placebo 335 
Intranasal oxytocin sprays were formulated by JW Pharmaceuticals (Seoul, South Korea) from 336 
oxytocin powder (Hemmo Pharmaceuticals, Mumbai, India). First, 35.2 mg of oxytocin (568 U) were 337 
mixed into 300 mL of 0.9% sodium chloride solution for which the pH was adjusted to 4.01 with 10× 338 
diluted acetic acid. The placebo spray (pH 4.01) was also formulated with 0.9% sodium chloride 339 
solution and acetic acid, but without the peptide. The filtered and sterilized solutions were sealed in 340 
1.5 mL vials and frozen. On the day of use, the vials were thawed and kept in a refrigerator (4°C) until 341 
required. A clinician prepared the nasal spray by transferring oxytocin or the placebo from the vial 342 
into a nebulizer. The nebulizer was primed and given to the participants to self-administer the nasal 343 
spray while being monitored by a clinician. 344 
 345 
Supplementary Information 2 346 
Study flow 347 
The participants were tested in a private room at Seoul Paik Hospital. The experiments were carried 348 
out at 1430h, and the participants were instructed to eat lunch 2 hours before drug administration and 349 
to refrain from further eating and drinking (other than water). Alcohol and caffeine were prohibited on 350 
the day of the drug administration. Upon arrival, the participants completed baseline measurements 351 
for physical symptoms, including abdominal, neurological, dermatological, and cardiac. They were 352 
then asked to self-spray the full 1.5 mL dose of oxytocin or the placebo nebulizer into their two 353 
nostrils under the supervision of a clinician. Each oxytocin spray delivered 40 IU of oxytocin, an 354 
amount determined based on a recent review, which reported that short-term use of intranasal 355 
oxytocin of up to 40 IU (per dose) in male and female humans resulted in no detectable subjective 356 
changes in a controlled research setting (MacDonald et al., 2011). Each inhalation of the test solution 357 
into a single nostril contained approximately 4 IU of oxytocin. Subsequently, the participants received 358 
oxytocin or placebo in ten puffs delivered to alternating nostrils at 30 s intervals. Neither the 359 
participant nor the clinician was informed of the drug assignment on the day.  360 
Kim et al., 17 
 
After intranasal administration of oxytocin or placebo, the participants completed self-reported 361 
measurements to assess their psychological states. This was followed by the dot-probe task, which 362 
began 45 minutes after the administration of the drug. At the end of the day, each participant carefully 363 
completed follow-up measurements for adverse physical symptoms. The second appointment was 364 
then scheduled for 1 week after the first appointment.  365 
 366 
Supplementary Information 3 367 
Self-reported psychometric assessments 368 
1. Eating Disorder Examination – Questionnaire (Fairburn and Beglin, 1994)  369 
The EDE-Q assesses the main behavioral features of an eating disorder over the past 28 days based 370 
on a self-report. The questionnaire consists of 36 items on a 7-point forced choice rating scale that 371 
measures weight, shape, eating related concerns, and dietary restrictions. The Korean EDE-Q is a 372 
reliable and valid instrument, and the Cronbach’s alpha of the Korean EDE-Q is 0.93 for the global 373 
scale and 0.79~0.92 for the 4 subscales (Lim et al., 2010). 374 
 375 
2. State-Trait Anger Expression Inventory (STAXI) (Spielberger, 1991) 376 
The STAXI is a 44-item, self-report questionnaire that evaluates different facets of anger on a five-377 
point scale: State Anger (the intensity of feeling angry, 10 items), Trait Anger (disposition toward 378 
anger, 10 items), Anger-in (proneness to suppressing anger, 8 items), Anger-out (tendency to express 379 
anger towards other people and objects, 8 items), and Anger Control (tendency to control the 380 
expression of anger, 8 items). Items are rated using 4-point Likert responses. The STAXI has been 381 
validated for various normal and clinical populations and has good psychometric properties (the 382 
internal consistency of the STAXI-2 scales and subscales ranging from 0.73 to 0.95). The Korean 383 
adaptation of STAXI (STAXI-K) (Chon, 1996) has the same factor structure as the original STAXI, 384 
although four items were replaced with newly constructed items. STAXI-K has a good internal 385 
consistency with a Cronbach’s alpha of over 0.70, except for Anger-in for female participants (0.69). 386 
The test-retest reliability coefficient of the STAXI-K over a 3-week period was also stable. 387 
Kim et al., 18 
 
3. Difficulties in Emotional Regulation Scale (DERS) (Gratz and Roemer, 2004).  388 
DERS is a 36-item self-report scale measuring emotional regulation. The participant is asked to rate 389 
responses across a five-point scale: 1=almost never (0–10%), 2=sometimes (11–35%), 3=about half 390 
the time (36–65%), 4=most of the time (66–90%) and 5=almost always (91–100%). There are six 391 
discrete, but interconnected subscales and a total score. Higher scores indicate greater difficulties with 392 
regulating emotions. The six subscales are as follows: (1) Non-acceptance of emotional responses, 393 
which is a tendency to have negative secondary responses to one’s own negative emotions or not 394 
accepting emotional reactions to distress; (2) Difficulties in engaging in goal-directed behavior, which 395 
involve difficulties concentrating and accomplishing tasks when experiencing negative emotions; (3) 396 
Impulse control difficulties, which are difficulties with remaining in control of behavior when 397 
experiencing negative emotions; (4) Lack of emotional awareness, which are difficulties associated 398 
with attending to and acknowledging emotions; (5) Limited access to emotion regulation strategies, 399 
which is a belief that, once upset, little can be done to regulate emotions, and (6) Lack of emotion 400 
clarity, which is how much an individual knows and understands the emotions they are experiencing. 401 
We used the Korean DERS (Cho, 2007), in which the Cronbach’s α for the total score was 0.92, 402 
comparable to Gratz and Roemer’s (2004) score of 0.93. Like Gratz & Roemer, Cronbach’s α values 403 
for the subscales of the Korean version were in the range of 0.76~0.89. 404 
 405 
4. Other measurements  406 
Depression and anxiety levels were assessed for each subject using the standardized Korean 407 
versions of the Beck Depression Inventory (BDI) (Beck et al., 1961) and the Spielberger State and 408 
Trait Anxiety Inventory (STAI) (Spielberger et al., 1983 ), respectively.  409 
 410 
 411 
 412 
 413 
 414 
Kim et al., 19 
 
Supplementary Information 4 415 
Trial structure and experimental conditions of the visual probe detection task  416 
Our target stimuli consisted of 60 images of adults showing 15 happy or 15 angry expressions 417 
where each adult had a corresponding picture showing a neutral expression (15 non-target stimuli). 418 
The target stimuli were paired with matched non-target stimuli. The task consisted of eight practice 419 
trials followed by 160 experimental trials.  420 
As the two images disappear from the screen in a trial, one of the two probes (‘:’ or ‘··’) appear 421 
at the centre of one of the two pictures that used to be there. The participants were then required to 422 
press one of two buttons on a keyboard (marked with white stickers) corresponding to the probe (Q 423 
for ‘:’ and Z for ‘··’). When a response was made, the probe disappeared and the next trial started. 424 
The participants were advised to identify the probe as quickly and accurately as possible. The target 425 
stimuli positions and the probe positions were balanced across trials, so each appeared in either 426 
location (right or left; probe behind the target or non-target) with equal frequency, following the 427 
paradigm of Mogg and Bradley (1998). Attention was measured as the time taken to correctly respond 428 
to the probe. The participant was assumed to more readily respond to the probe if her attention was 429 
already allocated to the place where the probe appears. A quicker response occurred when the probes 430 
appeared behind the target stimuli as opposed to when they appeared behind non-target stimuli. This 431 
was interpreted as vigilance for a threat. The dot-probe task was presented on the E-Prime software 432 
version 2 (Psychology Software Tools, Inc., Pittsburgh, PA, USA).  433 
We followed a standard analytical procedure for the visual probe task (Bradley et al., 1999). Only 434 
RTs from trials in which probes were correctly identified were included in the analysis. The correct 435 
response rates were 99.9% for the BN group and 99.7% for the HC group. Mean RTs were calculated 436 
for each participant, and the outlier trials were removed by excluding detection latencies beyond two 437 
standard deviations from their mean (i.e., from each individual’s mean RTs across all stimuli).  438 
 439 
 440 
 441 
Kim et al., 20 
 
Supplementary Information 5 442 
 443 
Happy expression                                                       Angry expression 444 
 445 
Fig S1. Attentional bias scores for the angry/happy faces under oxytocin/placebo conditions in 446 
patients with BN and the healthy women. There were no significant effects from the Drug x Emotion 447 
x Group interaction [F(1,228.082)=0.002, p=0.965] or Emotion [F(1,228.082)=0.136, p=0.712] on the 448 
AB scores. However, the model revealed significant effects from the Drug x Emotion interactions 449 
[F(1,228.082)=6.413, p=0.012] and Drug [F(1,228.082)=6.118, p=0.014], with oxytocin reducing the 450 
AB towards angry face in both the patients with BN and the HC participants. A simple effect test 451 
showed that the AB to angry faces was attenuated by oxytocin [F(1,120.632)=10.217, p=0.002]. 452 
Whereas, the AB to happy faces was not affected by oxytocin [F(1,118.034)=0.002, p=0.962]. 453 
*HC = healthy comparisons, BN = patients with bulimia nervosa 454 
 455 
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Exploratory analyses 457 
We additionally explored whether oxytocin induced changes in AB scores correlated with the 458 
difficulties regarding emotional regulation. AB delta scores were calculated by subtracting the AB 459 
scores in the oxytocin session from the AB scores in the placebo session. Thus, positive delta scores 460 
indicated greater AB toward stimuli in placebo conditions while negative delta scores indicated 461 
greater AB towards stimuli in oxytocin conditions. Consequently, correlation analyses were 462 
conducted to investigate the significant correlation between the delta and psychometric variables.  463 
Kim et al., 21 
 
In the exploratory analysis, AB to angry faces were negatively correlated with EDE-Q in patients 464 
with BN (global: r = -0.48, p = 0.006; restraint: r = -0.42, p = 0.017; eating concern: r = -0.45, p = 465 
0.010; shape concern: r = -0.36, p = 0.044; weight concern: r = -0.38, p = 0.034), but not in the HC 466 
group (all p-values for global and 4 subscales : p>0.1) for placebo conditions. In HC, AB correlated 467 
only with the anger trait (r=0.37, p=0.034) and anger expression (r=0.45, p=0.009) in STAXI.  468 
In the correlation analyses between the AB delta scores and difficulties with emotional regulation, 469 
there is a negative correlation of the AB delta scores with anger expression in STAXI subscales (r = -470 
0.508, p = 0.004) and a positive correlation with difficulties engaging in goal-directed behaviour 471 
(DERS_goals) (r = 0.408, p = 0.023) in patients with BN. In HC, the AB delta correlated only with 472 
anger-expression (r = 0.46, p = 0.007). Table S1 shows the results of correlations between AB and 473 
psychometric variables in BN and HC groups. 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
 483 
 484 
 485 
 486 
 487 
Kim et al., 22 
 
Supplementary Information 7 – Table S1. Correlations between the attentional bias scores to angry faces under oxytocin or placebo conditions, as well as psychological 
variables in patients with bulimia nervosa (n=31) and healthy women (n=33) 
 AB AB delta 
 Total (n=64) BN (n=31) HC (n=33) Total (n=64) BN (n=31) HC (n=33) 
 r p r p r p r p r p r p 
EDE-Q             
 Restraint -0.18 0.150 -0.42* 0.017 0.14 0.438 0.07 0.576 -0.26 0.145 0.11 0.540 
 Eating Concern -0.25* 0.042 -0.45* 0.010 -0.28 0.118 -0.04 0.770 -0.23 0.212 -0.27 0.134 
 Shape Concern -0.18 0.161 -0.36* 0.044 -0.08 0.621 0.09 0.523 -0.08 0.657 -0.12 0.499 
 Weight Concern -0.14 0.271 -0.38* 0.034 0.03 0.852 0.15 0.264 -0.07 0.690 -0.02 0.879 
 Global -0.21 0.089 -0.48** 0.006 -0.04 0.825 0.07 0.576 -0.20 0.276 -0.08 0.649 
BDI -0.05 0.666 -0.16 0.367 0.04 0.829 0.08 0.530 -0.04 0.815 -0.14 0.423 
STAI             
 State -0.08 0.528 -0.27 0.139 0.07 0.679 0.14 0.305 -0.18 0.329 0.08 0.651 
 Trait -0.01 0.896 -0.14 0.431 0.06 0.733 0.13 0.330 0.02 0.876 0.01 0.929 
STAXI              
Anger_State -0.08 0.525 -0.13 0.456 -0.01 0.932 0.08 0.547 -0.10 0.573 -0.19 0.285 
Anger_Trait 0.24 0.052 0.13 0.472 0.37* 0.034 0.05 0.706 0.18 0.318 0.23 0.187 
Anger_Supression -0.12 0.343 -0.18 0.314 -0.06 0.713 0.05 0.727 -0.01 0.939 -0.11 0.526 
Anger_Expression 0.26* 0.033 0.09 0.603 0.45** 0.009 0.23 0.095 0.22 0.216 0.46** 0.007 
Anger_Control -0.28* 0.023 -0.34 0.058 -0.22 0.208 -0.20 0.138 -0.51** 0.004 -0.22 0.203 
DERS    0.15 0.392 0.02 0.887   0.21 0.250 0.00 0.972 
Non-acceptance 0.01 0.888 0.08 0.655 -0.05 0.756 0.20 0.138 0.07 0.698 -0.06 0.727 
Goals 0.07 0.555 0.14 0.428 -0.02 0.892 0.21 0.133 0.40* 0.023 -0.03 0.873 
Impulsivity -0.00 0.985 0.03 0.835 -0.05 0.780 0.06 0.640 0.17 0.365 -0.16 0.335 
Awareness 0.13 0.281 0.33 0.069 -0.07 0.689 -0.13 0.359 0.13 0.469 -0.09 0.618 
Strategies 0.00 0.978 -0.00 0.988 -0.02 0.907 0.13 0.330 0.05 0.786 0.05 0.767 
Clarity 0.16 0.199 0.06 0.737 0.33 0.067 -0.05 0.697 0.08 0.647 0.15 0.391 
AB = Attentional bias, AB delta (;Attentional bias delta) = AB scores of the placebo session - AB scores of the oxytocin session, BN = bulimia nervosa, HC = healthy 
comparison, EDE-Q = Eating Disorder Examination Questionnaire, BDI = Beck Depression Inventory; STAI-State =  Spielberger State and Trait Anxiety Inventory State 
Score, STAI-Trait = Spielberger State and Trait Anxiety Inventory Trait score, STAXI = State and the Trait Anger Expression Inventory, DERS = Difficulties in Emotion 
Regulation Scale, Non-acceptance = non-acceptance of emotional responses, Goal = difficulties engaging in goal-directed behaviour, Impulse = impulse control difficulties, 
Awareness = lack of emotional awareness, Strategies = limited access to emotion regulation strategies, Clarity = lack of emotional clarity, r = Pearson’s correlation coefficient. 
*p<0.05, ** p<0.01 
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CONSORT Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Excluded (n=8) 
  Not meeting inclusion criteria (n=8) 
BN (n=4), HC (n=4) 
 
  Other reasons (n=  ) 
Participants finally included (n=64) 
BN (n=31), HC(n=33) 
Allocated to intervention (n=76) 
 Received allocated intervention (n=72) 
 Did not complete allocated intervention (n=4) 
BN(n=3), HC(=1) 
Analysed (n=72) 
 Excluded from analysis (invalid data) (n=8) 
BN(n=5), HC(n=3) 
 
Enrollment 
Analysis 
∙ BN=Bulimia Nervosa 
HC=Healthy Control 
Allocation 
Assessed for eligibility (n=84) 
BN (n=43), HC(n=41) 
Randomized (within subject) (n= 76) 
BN (n=39), HC (n=37) 
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CONSORT checklist of information to include when reporting a randomised trial 
 
Section/Topic 
Item 
No Checklist item 
Reported on 
page No 
Title and abstract 
 1a Identification as a randomised trial in the title 2 
1b Structured summary of trial design, methods, results, and conclusions 2 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 3 
2b Specific objectives or hypotheses 3 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 5 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/A 
Participants 4a Eligibility criteria for participants 3-4 
4b Settings and locations where the data were collected 3 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually 
administered 
5 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 5-6 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 4 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 5 
8b Type of randomisation; details of any restriction (such as blocking and block size) N/A 
 Allocation 
concealment 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any 
steps taken to conceal the sequence until interventions were assigned 
 
N/A 
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mechanism 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions  
5 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing 
outcomes) and how 
5 
11b If relevant, description of the similarity of interventions 5 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 6 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses N/A 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed 
for the primary outcome 
7 
13b For each group, losses and exclusions after randomisation, together with reasons 6 
Recruitment 14a Dates defining the periods of recruitment and follow-up N/A 
14b Why the trial ended or was stopped 5 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table1 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original 
assigned groups 
Table 1,2 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 
95% confidence interval) 
Table 1,2 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended N/A 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified 
from exploratory 
 
N/A 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) N/A 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 8 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 8 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 8 
Other information  
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Registration 23 Registration number and name of trial registry 4 
Protocol 24 Where the full trial protocol can be accessed, if available 4 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 9 
                                                                                                                               Kim et al. 27 
 
Supplementary references 
 
Beck, A.T., Ward, C.H., Mendelson, M., Mock, J.E., Erbaugh, J., 1961. An inventory for measuring 
depression. Archives of General Psychiatry 4, 561-571. 
Cho, Y., 2007. Assessing emotional dysregulation: Psychometric properties of the Korean version of 
the Difficulties in Emotion Regulation Scale (DERS). The Korean Journal of Clinical 
Psychology 26, 1015-1038. 
Chon, K.K., 1996. Development of the Korean State-Trait Anger Expression Inventory. The Korean 
Journal of Rehabilitation Psychology 3, 53-69. 
Fairburn, C., Beglin, S., 1994. Assessment of eating disorders—Interview or self-report questionnaire. 
International Journal of Eating Disorders 16, 363–370. 
Gratz, K.L., Roemer, L., 2004. Multidimensional assessment of emotion regulation and dysregulation: 
Development, factor structure, and initial validation of the difficulties in emotion regulation 
scale. Journal of Psychopathology and Behavioral Assessment 26, 41-54. 
Lim, S.J., Lee, Y.H., Heo, S.Y., Rhee, M.K., Choi, Y.M., Kim, M.S., Kim, Y.K., 2010. Reliability and 
Factor Structure of The Korean Version of Eating Disorder Examination Questionnaire. The 
Korean Journal of Health Psychology 6, 345-355. 
MacDonald, E., Dadds, M., Brennan, J., Williams, K., Levy, F., Cauchi, A., 2011. A review of safety, 
side-effects and subjective reactions to intranasal oxytocin in human research. 
Psychoneuroendocrinology 36, 1114-1126. 
Mogg, K., Bradley, B.P., 1998. A cognitive-motivational analysis of anxiety. Behaviour Research and 
Therapy 36, 809-848. 
Spielberger, C., 1991. State-Trait Anger Expression Inventory. Psychological Assessment Resources, 
Odessa, FL. 
Spielberger, C.D., Gorsuch, R., Lushene, R., Vagg, P., Facobs, G., 1983 Mannual for the State-Trait 
Anxiety Inventory, STAI (Form Y). Consulting Psychologists Press, Palo Alto. 
 
 
